Eikon Therapeutics develops new medicines using advanced technologies like single-molecule tracking and high-performance computing to accelerate drug discovery and development.

Clear Labs develops next-generation sequencing platforms that integrate DNA sequencing, robotics, and cloud-based bioinformatics for diagnostics.

Saluda Medical develops and commercializes the Evoke® System, a closed-loop spinal cord stimulation device for managing chronic pain.

Kobold Metals uses AI to identify and develop critical mineral deposits essential for the energy transition.

SandboxAQ develops quantum physics-based software for applications in life sciences, materials science, navigation, encryption, and cybersecurity.

nChroma Bio develops innovative genetic medicines using epigenetic editing and non-viral delivery technologies to treat chronic hepatitis B and D.

Metsera is a clinical-stage biopharmaceutical company developing next-generation treatments for obesity and metabolic diseases using their innovative platforms and Nutrient-Stimulated Hormone analog peptides.

Waymo develops and operates autonomous vehicle technology, focusing on expanding its robotaxi ride-hailing services.

Seaport Therapeutics develops neuropsychiatric medicines using its Glyph technology platform to enhance oral bioavailability and reduce side effects, with a focus on treating depression, anxiety, and other disorders.

Lightmatter is a company that develops photonic chip technology to enhance AI and high-performance computing with a focus on reducing power consumption and increasing performance.

Aktis Oncology is a clinical-stage biotechnology company developing a proprietary radiopharmaceutical pipeline, including Nectin-4-targeted miniprotein radioconjugates, for cancer treatment.

Arsenal Biosciences, Inc. is a clinical-stage company developing programmable T cell therapies for solid tumor cancers using a computationally driven approach.

Odyssey Therapeutics is a biotech firm specializing in developing precision immunomodulators and oncology medicines, with plans to advance multiple therapeutic programs into clinical studies.

RefleXion Medical develops and commercializes SCINTIX therapy, a novel treatment for all stages of indicated solid tumor cancers, including metastatic disease, delivered via the RefleXion X1 platform.

Apiture provides digital banking solutions, including the Apiture Digital Banking Platform, with an API-first approach and flexible solutions for over 300 banks and credit unions in the U.S.

Stash is a fintech company that offers an investing app, aiming to provide an affordable way for lower and middle-income consumers to invest, and has raised $40 million through a convertible note to reach profitability and plans to go public in the near future.

Avalyn Pharma is a biopharmaceutical company that develops inhalation therapies for rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases, with a focus on creating new inhaled formulations of approved medicines.

Databricks is a data and AI company that provides a platform utilized by over 10,000 organizations globally, including more than half of the Fortune 500 companies, and has completed a Series I funding round to accelerate AI technology development and expand its team.

Generate:Biomedicines is a clinical-stage biotherapeutics company that uses a machine-learning-powered generative biology platform to develop new drugs across oncology, immunology, and infectious disease.

Sortera Technologies is a material sorting company that uses artificial intelligence data analytics to sort pre-production aluminum and end-of-life mixed metals, enabling the use of recycled material in manufacturing, reducing costs and pollution, and increasing availability for domestic manufacturers.

Redwood Materials is a startup that specializes in recycling batteries, with a goal to recycle 300-500 GWh of batteries annually by 2030 or 2035.

Rapport Therapeutics is a clinical-stage biotechnology company that develops precision neuromedicines for seizure and psychiatric disorders by targeting specific neuroanatomical regions, aiming to provide better alternatives to current treatments by reducing unwanted drug-target interactions.